Janssen Pharmaceuticals Nv

BEERSE, Belgium, December 12, 2011 - Benefit of bortezomib, in combination with melphalan and prednisone (VMP), seen across multiple patient subgroups regardless of subsequent extensive therapy Janssen-Cilag International NV announced today that treatment with VELCADE(bortezomib), in combination with melphalan and prednisone (VMP), delivered a significant long-term overall survival (OS) benefit of 13.3 months (HR 0.695, p=0.0004), compared to treatment with melphalan-prednisone (MP), in patients with previously untreated multiple myeloma (MM), a fatal blood cancer.[1] The data, the result of the updated OS analysis of the landmark VISTA trial after 5 years of follow-up, are being presented today at the 53rd American Society for Hematology (ASH) annual meeting in San Diego.

BEERSE, Belgium, December 9, 2011 - Landmark VELCADE(bortezomib) five-year follow-up data in previously untreated multiple myeloma to be featured in oral presentation Janssen-Cilag International NV announced today that 9 abstracts, involving both the experimental molecule siltuximab and the established therapy VELCADE, have been accepted for presentation at this year's American Society of Hematology (ASH) annual meeting, to be held December 10-13, 2011, in San Diego, USA.